Acrylamide is an α,β-unsaturated vinyl monomer that causes cytotoxicity due to its alkylating properties. In recent years several proteins have been identifi ed that are alkylated by acrylamide in vivo. This fi nding might explain the neurotoxic effects of acrylamide in humans. However, the list of potential acrylamide target proteins is far from being complete. In particular, the proteins that mediate the cytotoxicity of acrylamide in cell cultures remained unknown. Here we identify two novel acrylamide target proteins in human cell cultures (Jurkat, HepG2 and Caco-2), adenosine deaminase and thioredoxin.
Introduction
Acrylamide is a neurotoxic α,β-unsaturated vinyl monomer. Laboratory animals treated with acrylamide develop ataxia and skeleton muscle weakness (LoPachin, 2005) , a phenotype that is mainly caused by degradation of nerve terminal end (LoPachin et al., 2002) . Due to the electrophilic character of the terminal methylene group of acrylamide it was speculated that acryl amide induces neurodegeneration via alkylation of sulfhydryl groups in proteins (Lopachin and Decaprio, 2005) . Recently it was shown that acryl amide indeed alkylates N-ethylmaleimide sensitive factor and SNAP-25 in vivo (Barber and LoPachin, 2004) . Using ICAT as a competitive label for cysteines, Barber et al. (2007) showed that acrylamide treatment reduces the number of reactive cysteines in a variety of rat striatal synaptosome proteins indicating that a vast number of proteins are alkylated by acrylamide in vivo.
The alkylation of cysteine residues via Michael addition is in fact unspecifi c and occurs in all tissues which have a slight alkaline pH regime. For instance, haemoglobin is the major target for acryl amide alkylation in vivo. Unspecifi c alkylation by acrylamide may also be the reason for the observed cytotoxicity and reproductive dysfunctions in laboratory animals (Chapin et al., 1995; Tyl and Friedman, 2003) and in cell cultures (Walmod et al., 2004) .
In the present study we tried to identify new proteins that undergo alkylation by acrylamide in three human cell cultures. We have treated three human cell lines (Jurkat, Caco-2 and HepG2 cells) with acrylamide and analyzed extracted proteins by MALDI-TOF for potentially alkylated candidates. With this approach we identifi ed two novel acrylamide target proteins that may contribute to the toxicity of acrylamide in cell cultures.
Material and Methods

Cell cultures
Jurkat (human leukaemia T cells) and HepG2 (human hepatocellular carcinoma cells) cells were maintained in RPMI 1640 medium (Invitrogen, Karlsruhe, Germany), supplemented with 10% heat-inactivated fetal bovine serum, 2 mM glutamine, 100 units/mL penicillin, and 100 µg/mL streptomycin (Invitrogen (Invitrogen), supplemented with 10% heat-inactivated FBS, 2 mM glutamine, 1 mM sodium pyruvate (Biowittaker, Walkersville, MD, USA), 10 mM non-essential amino acids (Bio wittaker), 100 units/ mL penicillin, and 100 µg/mL streptomycin. Cells were grown at 37 °C in a humidifi ed atmosphere of 5% CO 2 in 75-cm 2 culture fl asks (Greiner bioone, Fricken hausen, Germany).
Analysis of cell viability
Cytotoxicity was assessed with MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide; Sigma-Aldrich, Munich, Germany] assays. Exponentially growing cells were plated in 96-well plates and treated with various concentrations of acrylamide or propionamide (Sigma-Aldrich) dissolved in sterile water. Cells were incubated at 37 °C for 48 h. Then 0.05 mg/mL MTT were added to each well and incubation was continued for 2 and 4 h. MTT-formazan products were dissolved in water and absorbance was detected at 540 nm in an ELISA plate reader. Cell viability was calculated relative to untreated control cells. The assays were performed in 4 to 8 replicates and repeated at least 3 times.
2D-Gel electrophoresis
Cells were seeded in 75-cm 2 cell culture fl asks. After 2 d of incubation 2 mM acrylamide was added and cells were incubated for 18 h. Cells were harvested after trypsin treatment, washed with PBS and resuspended in 50 µL lysis buffer (8 M urea, 4% CHAPS, 1% DTT, 1 tablet complete protease inhibitor cocktail/50 mL). Cell debris was removed by centrifugation at 16,000 × g for 1 h at 4 °C. 50 µL of the supernatant were added to 300 µL rehydration buffer (8 M urea, 2% CHAPS, 0.2% DTT, 0.5% IPG buffer) and the mixture was applied onto IPG strips, pH 4 -7. Rehydration was performed at 50 V for 12 h. Isoelectric focusing was performed according to the following program: 200 V for 1 h, 500 V for 1 h, 1000 V for 1 h, linear gradient to 8000 V within 1 h and 8000 V for 6 h. After isoelectric focussing, IPG strips were equilibrated in SDS buffer (50 mM Tris-HCl, pH 8.8, 6 M urea, 2% SDS, 2% DTT, 30% glycerol) for 30 min for the second dimension. Reduced cysteines were alkylated with iodoacetamide (2.5% in equilibration buffer) and IEF gels were placed on 12% SDS-PAGE gels. In order to exclude secondary alkylation with acrylamide monomers during the electrophoresis SDS-PAGE gels were polymerized overnight. Then SDS-PAGE (12%) was performed at 20 mA for 30 min and 40 mA for 3 h, and proteins were stained with colloidal Coomassie blue.
MALDI-TOF analysis
Excised gel plugs were washed with 100 µL water, 100 µL 50% acetonitrile and subsequently shrinked in 100 µL acetonitrile. Gel slices were rehydrated at 4 °C in 25 mM NH 4 HCO 3 , pH 8, containing 12 ng/µL trypsin (Promega, Madison, USA) for 1 h. Tryptic digestion was performed at 56 °C for 1 h. Peptides were extracted from the gel plugs with 20 µL of 5% formic acid and desalted using ZipTips (Millipore, Madison, USA). The eluted peptides were spotted onto the target plate, air-dried and covered with 0.5 µL alpha-cyano-4-hydroxycinnamic acid. MALDI-TOF analysis was performed on an Ultrafl ex mass spectrometer (Bruker Daltonics, Bremen, Germany). Mass spectra were obtained in the positive-ion mode at an acceleration voltage of 25 kV and a pulsed ion extraction time of 80 ns. Typically 300 shots were combined for one spectrum. MALDI-TOF and PSD spectra were searched against the NCBI non-redundant database using MASCOT (Matrix Science, London, UK).
In vitro adenosine deaminase activity assay
Increasing concentrations of acrylamide (0, 0.6, 1.3, 2.5, 5.0, 10.0 and 20.0 mM) were dissolved in 100 µL of PBS, pH 7.4, or 0.05 M Tris-HCl, pH 8.8, and applied into a 96-well plate. Adenosine deaminase (calf intestine mucosa, Sigma-Aldrich) was dissolved in PBS, pH 7.4 (fi nal concentration 0.05 units/mL). 10 µL of enzyme solution were added to each well and incubated for 20 min at 37 °C. 10 µL of 0.45 mM adenosine solution (in PBS) were added to each well, and the enzyme kinetics was recorded at 265 nm against controls in one-minute steps at room temperature.
Results
Acrylamide exhibits dose-dependent toxicity on human cell cultures
In order to investigate the toxicity of acryl amide on human cell cultures, different concentrations of acrylamide were added to Jurkat, Caco-2 and HepG2 cells. Cell viability was measured after acrylamide exposure with neutral red and the MTT assay. As shown in Fig. 1 , acryl amide exhibited a signifi cant dose-dependent toxicity on all three cell lines. Two days after seeding, HepG2 cells and Jurkat cells showed similar toxic effects, whereas Caco-2 cells exhibited a slightly, but signifi cant (p < 0.01) higher cell viability (see calculated IC 50 values in Table I ). Interestingly, the acrylamide-induced cell toxicity was signifi cantly lower (p < 0.01) in 7-day-old HepG2 cells compared to 2-day-old cells. Hence our data are in agreement with previously reported results for acrylamide-treated RT4 cells (Tanii et al., 1988) . In order to test whether the cytotoxicity is based on the alkylating properties of acrylamide we treated the same cells with propionamide, an α,β-saturated acrylamide analogue. In contrast to the effect of acrylamide, propionamide did not exhibit any toxic effects at the given concentrations (Fig. 2) . This fi nding clearly indicates that the terminal methylene group of acrylamide is mediating the biochemical reactions in the cells.
Acrylamide alkylates adenosine deaminase (ADA) and thioredoxin (TRX)
Modifi cation of sulfhydryl groups in proteins appears to be the molecular mechanism of acrylamide toxicity. In order to identify proteins with a covalent bonding to acrylamide we separated total protein extracts of acrylamide-treated cells (10 µM acrylamide, cells treated for 20 h) by 2D-gel electrophoresis. From these 2D-gels, 32 high abundant spots were excised, digested with trypsin and analyzed by MALDI-TOF/TOF. The MALDI-TOF spectra were then searched for propionamide adducts (additional mass of 71 Da) using the MASCOT database. From the 32 analyzed proteins, two proteins, ADA (Cys-74, Jurkat cells) and TRX (Cys-73, Caco-2 cells) were found to be alkylated ( Fig. 3 ; Table II ). Both modifi cations were confi rmed by PSD fragmentation of the alkylated peptide. An effect on other proteins is not excluded.
Acrylamide does not reduce ADA activity
Cys-74 of ADA, which was found to be alkylated by acrylamide, is not located in the active pocket C D (Wilson et al., 1991; Sharff et al., 1992) and, therefore, we wondered whether alkylation of Cys-74 has an effect on ADA activity. In order to investigate if the enzymatic activity of ADA is reduced due to alkylation we treated commercial adenosine deaminase with different concentrations of acrylamide. Then we measured the activity of the enzyme with various concentrations of adenosine.
However, no reduction of the ADA activity was detected.
Discussion
Acrylamide is a well documented neurotoxin in humans and causes reproductive dysfunctions in animals. Acrylamide is also cytotoxic in cell- Table II . Identifi ed proteins and acrylamide-modifi ed peptides. Proteins were identifi ed after digestion with trypsin by MALDI-TOF/TOF. The MASCOT score refers to a peptide tolerance of 180 ppm and a signifi cant score of 63 (p < 0.05) except * which were identifi ed by a combination of TOF and PSD spectra (signifi cant score 36). ** Sequences were confi rmed by PSD; *** unconfi rmed sequences; b, mixture of proteins; acr, acrylamide-modifi ed cysteinyl. amide. Therefore, we tested the toxicity of acrylamide in three well established human tumour cell cultures (HepG2, Jurkat and Caco-2 cells). Acrylamide showed dose-dependent cytotoxic effects in all three tested cultures. In contrast, the C1-C2 saturated analogue propionamide, a common negative control substance (Sickles et al., 1996; Stone et al., 1999) , had no effect. The concentrations that caused serious cytotoxicity (2 -4 mM) were comparable to those of other alkylating reagents tested in cultured human and rat hepatocytes (Boot, 1996) . They were also similar to the IC 50 value of ifosfamide (a mustard alkylating agent) in rabbit proximal renal tubule cells (Springate et al., 1999) . Hence, our data confi rms that acrylamide causes cytotoxicity effects in cell cultures and this cytotoxicity is most likely mediated by protein alkylation. In order to identify alkylated proteins under cell culture conditions we extracted proteins from acrylamide-treated cells and analyzed them by 2D-gel electrophoresis and MALDI-TOF (Fig. 3) . Using these techniques we identifi ed two novel alkylated proteins. One alkylated protein was ADA in Jurkat cells (Table II) . ADA degrades the nucleotide and messenger molecule adenosine to inactive inosine. In many cells ADA is associated with the receptor for adenosine, adenosine receptor (CD26), and there are strong evidences that ADA is involved in the regulation the CD26 via degradation of adenosine. Hence ADA is a negative regulator of ADA-induced release of acetylcholine in T-lymphocytes in motor neurons.
The mass spectrum of acrylamide-treated ADA showed a dominant peak that corresponds to the alkylated peptide FDYYMPAIACR (Fig. 3A) . Fragmentation of this peptide confi rmed the sequence and showed that Cys-74 is alkylated after acrylamide treatment (Fig. 3B) . Cys-74, however, is not located in the active pocket of ADA (Wilson et al., 1991; Sharff et al., 1992) and it is unlikely that Cys-74 is necessary for complex formation with CD26 (Weihofen et al., 2004) . On the other hand, there are several evidences that modifi cations of cysteines affect the ADA activity. Lupidi et al. (1997) showed that the cysteinemodifying agent PCMBS reduces the ADA activity, and Arrendondo-Vega et al. (1998) isolated the ADA mutation G74C from cDNA of patients with severe and delayed onset combined immunodefi ciency. The authors reported further that the mutation G74C shows reduced ADA activity in vitro. We did not observe any changes in the ADA activity after acrylamide treatment in vitro. The discrepancy between our data and those of Lupidi et al. (1997) might be due to the nature of the reagent: In contrast to propionamide, a small neutral irreversible modifi cation, PCMBS is a relatively big, acidic compound that contains organic mercury. Hg 2+ is an inhibitor of ADA (Franco et al., 1998) , and traces of Hg 2+ in PCMBS might also contribute to the observed reduction in the ADA activity.
The other alkylation site is Cys-73 of the oxidoreductase TRX, found in Caco-2 cells (Table  II) . TRX Cys-73 facilitates the formation of enzymatically inactive homodimers Weichsel et al., 1996) , and modifi cation of Cys-73 affects the activity of TRX (Kirkpatrick et al., 1998; Casagrande et al. 2002) . Activated TRX promotes the proliferation of cancer cells, and recently it was shown that 2-imidazolyl disulfi des, a class of anticancer agents, inhibit the growth of MCF-7 breast cancer cells by irreversible modifi cation of Cys-73 (Kirkpatrick et al., 1997 (Kirkpatrick et al., , 1998 . Alkylation of Cys-73 with acrylamide is also an irreversible modifi cation and therefore most likely has similar effects. Therefore, TRX is a strong candidate for one of the proteins that mediate acrylamide-induced cytotoxicity.
